

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL239201508US

Express Mail Label Number

3/25/02

Date of Deposit


Form PTO-1390-MOD (REV 10-96)		U S Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER 4-31153A
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U S APPLICATION NO (If known, see 37 CFR 1.5)	
INTERNATIONAL APPLICATION NO. PCT/EP 00/09346	INTERNATIONAL FILING DATE 25 September 2000 (25.09.00)	PRIORITY DATE CLAIMED 27 September 1999 (27.09.99)	
TITLE OF INVENTION PROCESS FOR PHENYLACETIC ACID DERIVATIVES			
APPLICANT(S) FOR DO/EO/US ACEMOGLU ET AL.			

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau. (See Form PCT/IB/308)
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).
10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).


Items 11. to 16. below concern document(s) or information included.

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A **FIRST** preliminary amendment.
 A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. A substitute specification.
15. A change of power of attorney and/or address letter.
16. Other items or information:

U.S. APPLICATION NO (if known, see 37 CFR 1.16)	INTERNATIONAL APPLICATION NO	ATTORNEY'S DOCKET NUMBER		
10/089058	PCT/EP 00/09346	4-31153A		
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):		CALCULATIONS PTO USE ONLY		
Search Report has been prepared by the EPO or JPO		\$890		
International preliminary examination fee paid to USPTO (37 CFR 1.482)		\$710		
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))		\$740		
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....		\$1,040		
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).		\$100		
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 890		
Surcharge of \$130 for furnishing the oath of declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	7	- 20 =	0	X \$ 18 \$
Independent claims	2	- 3 =	0	X \$ 84 \$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 280 \$	
TOTAL OF ABOVE CALCULATIONS =		\$ 890		
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).		\$		
SUBTOTAL =		\$ 890		
Processing fee of \$130 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$		
TOTAL NATIONAL FEE =		\$ 890		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property		\$		
TOTAL FEES ENCLOSED =		\$ 890		
		Amount to be: \$		
		refunded \$		
		charged \$		
<p>a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$890 to cover the above fees. A duplicate copy of this form is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis Corporation.</p>				
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>				
<p>Send all correspondence to the address associated with Customer No. 001095, which is currently:</p> <p>Thomas Hoxie Novartis Corporation Patent and Trademark Dept. 564 Morris Avenue Summit, NJ 07901-1027</p>				
<p> Carol A. Loeschorn Attorney for Applicants Reg. No. 35,590 (908) 522-6932</p>				

PROCESS FOR PHENYLACETIC ACID DERIVATIVES

The present invention relates to processes for the production of 2-phenylamino-5-alkylphenyl acetic acids (the compounds of formula I given below), intermediates therefor and pharmaceutically acceptable salts thereof and pharmaceutically acceptable prodrug esters thereof;




wherein

- R is methyl or ethyl;
- R₁ is chloro or fluoro;
- R₂ is hydrogen or fluoro;
- R₃ is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy;
- R₄ is hydrogen or fluoro; and
- R₅ is chloro, fluoro, trifluoromethyl or methyl,

provided that R₁, R₂, R₄ and R₅ are not all fluoro when R is ethyl and R₃ is H.

Accordingly in a first aspect the invention provides a process for the production of a compound of Formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable and physiologically cleavable prodrug ester thereof, comprising cleaving a lactam of formula II



wherein the symbols are as defined above with a base.

The above processes may include, if desired, temporarily protecting any interfering reactive groups and then isolating the resulting compound of the invention; and, if desired, converting the free carboxylic acid of the compound of formula I into a pharmaceutically acceptable ester derivative thereof; and/or if desired, converting the free acid of formula I into a salt or a resulting salt into the free acid or into another salt.

The above processes may be carried out under conditions known in the art for the hydrolytic cleavage of lactams, preferably with a strong base, such as aqueous sodium hydroxide (e.g. a 30% aqueous solution of NaOH), optionally in the presence of a water miscible organic solvent such as ethanol or methanol, preferably at elevated temperature, e.g. at a temperature in the range from about 50° to 100°C, (for instance as generally described in US Patent 3,558,690). The resultant reaction mixture is conveniently neutralised with an acid, e.g. a mineral acid such as hydrochloric acid to give the free acid product of formula I, which may be recovered by crystallisation, e.g. on cooling of the reaction mixture to ambient temperature, and filtration.

Pharmaceutically acceptable prodrug esters are ester derivatives which are convertible by solvolysis or under physiological conditions to the free carboxylic acids of formula I. Such esters are e.g. lower alkyl esters (such as the methyl or ethyl ester), carboxy-lower alkyl esters such as the carboxymethyl ester, nitrooxy-lower alkyl esters (such as the 4-nitrooxybutyl ester), and the like.

Pharmaceutically acceptable salts represent metal salts, such as alkaline metal salts, e.g. sodium, potassium, magnesium or calcium salts, as well as ammonium salts, which are formed e.g. with ammonia and mono- or di-alkylamines, such as diethylammonium salts, and with amino acids such as arginine and histidine salts.

Preferred compounds of formula I which may be prepared according to the present invention include:

5-methyl-2-(2',4'-dichloro-6'-methylanilino)phenylacetic acid;

5-methyl-2-(2', 3', 5', 6'-tetrafluoroanilino)phenylacetic acid;

5-methyl-2-(2', 3', 4', 6'-tetrafluoroanilino)phenylacetic acid;

5-methyl-2-(2',6'-dichloroanilino)phenylacetic acid;

5-methyl-2-(2',6'-dichloroanilino)phenylacetic acid, potassium salt;

5-methyl-2-(2',6'-dichloroanilino)phenylacetic acid, sodium salt;

5-methyl-2-(2'-chloro-6'fluoroanilino)phenylacetic acid;

5-methyl-2-(2',6'-dichloro-4'-methylanilino)phenylacetic acid;

5-methyl-2-(2'-chloro-6'-methylanilino)phenylacetic acid;

5-methyl-2-(2',4'-difluoro-6'-chloroanilino)phenylacetic acid;

5-methyl-2-(2'-fluoro-4',6'-dichloroanilino)phenylacetic acid;

5-methyl-2-(2'-chloro-4'-fluoro-6'-methylanilino)phenylacetic acid;

5-ethyl-2-(2'-fluoro-6'-chloroanilino)phenylacetic acid;

5-ethyl-2-(2'-chloro-6'-methylanilino)phenylacetic acid;

5-ethyl-2-(2',3',6'-trifluoroanilino)phenylacetic acid;

5-ethyl-2-(2',3',5',6'-tetrafluoro-4'-ethoxyanilino)phenylacetic acid;

5-ethyl-2-(2'-chloro-4',6'-difluoroanilino)phenylacetic acid;

5-ethyl-2-(2',4'-dichloro-6'-fluoroanilino)phenylacetic acid;

5-ethyl-2-(2',4'-dichloro-6'-methylanilino)phenylacetic acid;

5-ethyl-2-(2'-fluoro-4'-chloro-6'-methylanilino)phenylacetic acid;

5-ethyl-2-(2',4'-difluoro-6'-methylanilino)phenylacetic acid;

5-ethyl-2-(2'-chloro-4'-fluoro-6'-methylanilino)phenylacetic acid;

5-methyl-2-(2'-chloro-4'-hydroxy-6'-fluoroanilino)phenylacetic acid;

5-methyl-2-(2'-fluoro-6'-trifluoromethylanilino)phenylacetic acid, and

5-methyl-2-(2',4'-dichloro-6'-trifluoromethylanilino)phenylacetic acid,

and pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.


Particularly preferred compounds of formula I which may be prepared according to the present invention include:

5-methyl-2-(2', 3', 4', 6'-tetrafluoroanilino)phenylacetic acid;
 5-methyl-2-(2',6'-dichloroanilino)phenylacetic acid;
 5-methyl-2-(2'-chloro-6'fluoroanilino)phenylacetic acid;
 5-methyl-2-(2',6'-dichloro-4'-methylanilino)phenylacetic acid;
 5-methyl-2-(2'-chloro-6'-methylanilino)phenylacetic acid;
 5-methyl-2-(2'-chloro-4'-fluoro-6'-methylanilino)phenylacetic acid;
 5-ethyl-2-(2'-fluoro-6'-chloroanilino)phenylacetic acid;
 5-ethyl-2-(2'-chloro-6'-methylanilino)phenylacetic acid;
 5-ethyl-2-(2',3',6'-trifluoroanilino)phenylacetic acid, and
 5-ethyl-2-(2',4'-dichloro-6'-methylanilino)phenylacetic acid,

and pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.

Thus, preferably also the processes of the invention may be used to prepare compounds of formula I in which R is methyl or ethyl; R₁ is chloro or fluoro; R₂ is hydrogen; R₃ is hydrogen, fluoro, chloro, methyl or hydroxy; R₄ is hydrogen; R₅ is chloro, fluoro or methyl; or a pharmaceutically acceptable salt or a pharmaceutically acceptable prodrug ester thereof.


The lactam of formula II may be prepared by oxidation of a lactam of formula III




wherein the symbols are as defined above.

Standard mild oxidation conditions may be used, such as heating with catalytical amounts of palladium on charcoal in a proper solvent, e.g. xylene.

The lactam of formula III may be prepared by coupling an aniline derivative of formula IV




wherein the symbols are as defined above, with a cyclohexanone derivative of formula Va or an amino substituted cyclohexene derivative of formula Vb



wherein R is ethyl or methyl and R' is lower alkyl or similar.


Coupling of IV with Va and Vb typically involves elimination of water or the secondary amine, HNR'_2 , e.g. under acidic conditions.

Vb may be prepared by reaction of the amino substitutes cyclohexene derivative of formula Vb'



wherein R and R' are as defined above, with methyl or ethyl glyoxylate. Vb may be converted to Va by hydrolysis, for instance as hereinafter described in the Examples.


Alternatively the lactam of formula II is obtained by cyclisation of a compound of formula VII



wherein the symbols are as defined above.

The cyclisation process is conveniently carried out under Friedel-Crafts alkylation conditions, e.g. in the presence of a Friedel-Crafts catalyst such as aluminium chloride or ethyl aluminium dichloride, preferably at elevated temperature, e.g. a temperature in the range from about 100° to about 180°C. The cyclisation reaction may be carried out in the presence of an inert solvent such as dichlorobenzene, or preferably a melt of the compound of formula VII is heated with the Friedel-Crafts catalyst.


The compound of formula VII is prepared by N-acylation of a diphenylamine of formula VIII



wherein the symbols are as defined above with a haloacetyl chloride.


For instance, the compound of formula VIII is heated, e.g. to about 80°C, with chloroacetylchloride. The product may be recovered by diluting the reaction mixture with solvent, e.g. 2-propanol, and crystallisation.

The compound of formula VIII may be obtained by rearrangement and hydrolysis of a compound of formula IX.




wherein the symbols are as defined above.

Conveniently the compound of formula IX is treated with an organic base, e.g. an alkali metal alkoxide such as sodium methoxide, preferably with heating, e.g. to a temperature of at least about 75°C. During this procedure an intermediate product of formula X,



wherein the symbols are as defined above, forms as a result of the initial rearrangement reaction, but undergoes direct cleavage under the prevailing reaction conditions to give the diphenylamine compound of formula VIII.

Alternatively the diphenylamine compound of formula VIII may be obtained by coupling of the corresponding halobenzene derivative of formula XI




where X is a halogen, e.g. I or Br, and the other symbols are as defined above with p-toluidine or 4-ethyl aniline.

Such a coupling reaction may be carried out by use of Buchwald chemistry. For example, the compound of formula XI and the p-toluidine or 4-ethyl aniline are mixed


with an organic base, e.g. sodium tertiary butylate, and an appropriate ligand, e.g. BINAP, in an organic solvent such as toluene; a palladium compound or catalyst precursor such as Pd(dba)₂ is added and the reaction mixture is heated. After cooling and treatment with acid, e.g. HCl, the diphenylamine product of formula VIII may be recovered from the organic phase of the reaction mixture.

In a further alternative, the diphenylamine compound of formula VIII may be obtained by coupling of the corresponding aniline derivative of formula IV




as defined above with 4-bromotoluene or 1-ethyl-4-bromobenzene. Such a coupling reaction may be carried out similarly by use of Buchwald chemistry. For example, the compound of formula IV and the 4-bromotoluene or 1-ethyl-4-bromobenzene are mixed with an organic base, e.g. sodium tertiary butylate in an organic solvent such as toluene; a palladium compound or catalyst precursor e.g. Pd(dba)₂, and a ligand, e.g. P(tBu)₃, or BINAP, are added to this reaction mixture which is then stirred at elevated temperature, e.g. 110°C, until completion of the reaction, e.g. overnight. Similarly the diphenylamine product of formula VIII may be recovered from the organic phase of the reaction mixture, for instance after cooling and treatment with acid, e.g. HCl.

The compound of formula IX may be prepared by alkylation of the corresponding phenol derivative of formula XII



wherein the symbols are as defined above, with 2-chloro-N-(4-methylphenyl)acetamide or 2-chloro-N-(4-ethylphenyl)acetamide. For instance, the compound of formula XII and 2-chloro-N-(4-methylphenyl)acetamide or 2-chloro-N-(4-ethylphenyl)acetamide are mixed in an organic solvent such as 2-propanol in the presence of a base, e.g. K_2CO_3 , and the reaction mixture boiled until completion of the reaction, e.g. for about 4 hours. 2-chloro-N-(4-methylphenyl)acetamide and 2-chloro-N-(4-ethylphenyl)acetamide may be prepared, e.g. *in situ*, by reaction of 4-methyl- or 4-ethylaniline with chloroacetyl chloride. The compound of formula IX may be recovered from the reaction mixture if desired. Preferably, however, the compound of formula IX is not isolated but is converted to the compound of formula VIII, by rearrangement and hydrolysis as described above carried out on the product reaction mixture resulting from the alkylation of the compound of formula XII.

Alternatively the diphenylamine of formula VIII may be prepared by oxidation of the corresponding compound of formula XIII (or tautomer thereof)



wherein the symbols are as defined above.

The dehydrogenation reaction may be carried out by classical methods, for instance by treatment with iodine, e.g. I_2 in THF/AcOH.

The compound of formula XIII may be prepared by coupling of 1-methoxy-4-methylcyclohexa-1,4-diene or 1-methoxy-4-ethylcyclohexa-1,4-diene with an aniline derivative of formula IV as defined above.

This coupling reaction may be carried out in the presence of a catalyst such as $TiCl_4$, in organic solvents e.g. THF and chlorobenzene, preferably with cooling, e.g. at about $-40^\circ C$.

1-methoxy-4-methylcyclohexa-1,4-diene or 1-methoxy-4-ethylcyclohexa-1,4-diene may be prepared by partial reduction of 4-methylanisole or 4-ethylanisole by


Birch reduction, e.g. by treatment with Na in liquid ammonia, for instance as described by Subba Rao et al. Australian Journal of Chemistry 1992, 45, p. 187-203.

Conveniently the compound of formula XIII is not isolated, but the coupling reaction between the compound of formula IV and the 1-methoxy-4-methylcyclohexa-1,4-diene or 1-methoxy-4-ethylcyclohexa-1,4-diene, is followed by oxidation to give the diphenylamine derivative of formula VIII.

In starting compounds and intermediates, which are converted to the compounds of formulae I to XIII in a manner as hereinbefore described, functional groups present such as amino, hydroxy and carboxyl groups, are optionally protected by conventional protecting groups that are common in preparative organic chemistry. Protected hydroxy, amino and carboxyl groups are those that can be converted under mild conditions into free amino, hydroxy and carboxyl groups without other undesirable side reactions taking place. For example, hydroxy protecting groups are preferably benzyl or substituted benzyl groups.

Processes for the preparation of the 2-phenylamino-5-alkylphenylacetic acid derivatives as described above are shown schematically on the following page.


Preparation of 2-Arylamino-arylacetic acids (COX-2 inhibitors)
Overview synthetic methodologies




The processes for the production of the compounds of formulae II, III, VII, VIII, IX, X and XIII as described above are included within the scope of the present invention.

Thus in further aspects the invention includes a process selected from


a) A process for the production of the lactam of formula II




which comprises oxidizing of a lactam of formula III



b) A process for the production of the lactam of formula II as defined above, which comprises cyclisation of a compound of formula VII



c) A process for the preparation of a compound of formula III as defined above comprising coupling an aniline derivative of formula IV




with a cyclohexanone derivative of formula Va or an amino substituted cyclohexene derivative of formula Vb




wherein R is ethyl or methyl and R' is lower alkyl or similar

d) A process for the production of a compound of formula VII which comprises N-acylation of a diphenylamine of formula VIII




with a haloacetyl chloride

e) A process for the preparation of a compound of formula VIII which comprises rearrangement and hydrolysis of a compound of formula IX.




f) A process for the production of a compound of formula VIII which comprises coupling of a halobenzene derivative of formula XI




in which X is halo, with p-toluidine or 4-ethyl-aniline;

- g) A process for the production of a compound of formula VIII which comprises coupling an aniline derivative of formula IV with 4-bromotoluene or 1-ethyl-4-bromobenzene;
- h) A process for the production of a compound of formula VIII which comprises cleavage of a compound of formula X




- i) A process for the formation of a compound of formula X which comprises rearrangement of a compound of formula IX
- j) A process for the production of a compound of formula IX which comprises alkylation of a compound of formula XII with 2-chloro-N-(4-methylphenyl)acetamide or 2 chloro-N-(4-ethylphenyl)acetamide
- k) A process for the production of a compound of formula VIII which comprises alkylation of a compound of formula XII with 2-chloro-N-(4-methylphenyl)acetamide or 2 chloro-N-(4-ethylphenyl)acetamide followed by rearrangement and cleavage of the intermediate compound of formula IX;
- l) A process for the production of a compound of formula VIII comprising oxidation of the corresponding compound of formula XIII (or tautomer thereof)



- m) A process for the production of a compound of formula XIII which comprises coupling 1-methoxy-4-methylcyclohexa-1,4-diene or 1-methoxy-4-ethylcyclohexa-1,4-diene with an aniline derivative of formula IV as defined above, and
- n) A process for the production of a compound of formula VIII comprising coupling 1-methoxy-4-methylcyclohexa-1,4-diene or 1-methoxy-4-ethylcyclohexa-1,4-diene with an aniline derivative of formula IV, followed by dehydrogenation
wherein all symbols used are as defined above.

One or more of the processes a) to n) above may be used in appropriate sequence (see the scheme given above) in the preparation of the compound of formula I.

Thus the invention further provides a process for the preparation of a compound of formula I



wherein the symbols are as defined above, which comprises one or more of processes selected from processes a) to n) as defined above, optionally in combination with a process according to the first aspect of the invention.


Still yet further the invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug ester thereof, when prepared by a process which comprises one or more of processes

a) to n) as defined above, preferably with a process according to the first aspect of the invention.


The compounds of formulae II, III, VII, VIII, IX, X and XIII are included per se within the scope of the present invention.

Thus in yet further aspects the invention provides a compound selected from:


a) A compound of formula II




b) A compound of formula III




c) A compound of formula VII




d) A compound of formula VIII



e) A compound of formula **IX**




f) A compound of formula **X**



and

g) A compound of formula **XIII**, or a tautomer thereof




wherein the symbols are as defined above.

Compounds of formula XII in which at one of R₁ or R₆ is chlorine and the other is fluorine may be prepared by methods known in the art of chlorination of phenols, preferably in the presence of catalytic amounts of a secondary amine, e.g. diisopropylamine. In a preferred embodiment according to the present invention, the chlorination reaction comprises simultaneous addition of chlorine and phenol to the reaction mixture, preferably using hexane fraction as the solvent. It has been found that simultaneous addition of at least part, preferably the majority, of the chlorine and the phenol to the reaction mixture gives rise to high productivity and selectivity in production of the desired product as compared with the unwanted side products. Furthermore use of hexane fractions permits isolation of the desired phenol product in high purity (e.g. 99%) by crystallisation.


The invention is further described by way of illustration only in the following Examples.

EXAMPLES


The diphenylamine compounds of Formula VIII



are prepared by Buchwald chemistry as described below in Examples 1 and 2, either by coupling of an aniline derivative of Formula IV




with 4-bromotoluene or 1-ethyl-4-bromobenzene as described in Example 1, or by coupling of a halobenzene derivative of Formula XI



with p-toluidine or 4-ethylaniline as described in Examples 2. The compounds of Formula VIII thus obtained may be converted into the corresponding compounds of Formula I by procedures as described below.

Example 1a

N-(2',3',4',6'-Tetrafluorophenyl)-4-methylaniline




A mixture of 2,3,4,6-tetrafluoroaniline (0.72g, 4.4 mmol), 4-bromotoluene (0.8g, 4.7mmol), toluene (55ml), sodium tert-butoxide (0.8g, 8.3mmol), tri-tert-butylphosphine (130mg, 0.64mmol) and bis-dibenzylideneacetone-palladium(0) (125 mg, 0.2mmol) is heated under nitrogen to 85°C for 3h. After cooling, water (50ml), concentrated aqu. HCl (10ml) and hyflo (1g) is added and stirring is continued for about one hour followed by filtration. The organic phase is washed with water twice, evaporated and the residue is subjected to flash chromatography on silica (45g) using heptane/toluene (2:1) as the eluent to afford N-(2',3',4',6'-Tetrafluorophenyl)-4-methylaniline (0.92g, 3.6 mmol) as an oil which crystallises (mp. 64-65°C).

¹H-NMR (400 MHz, DMSO-d6): 2.20 (s, 3H, CH₃); 6.63 [d, 8.2Hz, 2H, HC(2), HC(6)]; 6.99 [d, 8.2Hz, 2H, HC(3), HC(5)]; 7.56 [symmetrical m, 1H, HC(5')]; 7.84 (s, 1H, NH).

N,N-Bis-p-tolyl-2,3,4,6-tetrafluoroaniline is isolated as a byproduct, mp: 94.96°C.

Example 1b: N-(2',3',5',6'-Tetrafluorophenyl)-4-ethylaniline




A mixture of 2,3,5,6-tetrafluoroaniline (4.5g, 27.3 mmol), 4-ethylbromobenzene (5.0g, 27mmol), toluene (50ml), sodium tert-butoxide (4.67g, 48mmol), tri-tert-butylphosphine (217mg, 1.07mmol) and bis-dibenzylideneacetone-palladium(0) (260 mg, 0.45mmol) is heated under nitrogen to 85°C for 15.5h. The mixture is cooled to

room temperature and water (30ml), concentrated hydrochloric acid (20ml) and hyflo are added. After stirring for 45minutes, the mixture is filtered and the organic phase is washed with water three times. The solvent is evaporated in vacuo and the residue is chromatographed on silica usind hexane/toluene (9:1 to 3:1) affording N-(2',3',5',6'-tetrafluorophenyl)-4-ethylanilin as a liquid.

¹H-NMR (400MHz, CDCl₃): 1.26 (t, 3H, CH₃); 2.65 (q, 2H, CH₂); 5.65 (s, 1H, NH); 6.73 [tt, 1H, H-C(4')]; 6.88 [d, 2H, H-C(2,6)]; 7.15 [d, 2H, H-C(3,5)].

MS, m/z: 268 (M-H), 248 (M-HF).


Example 1c: N-(2'-Chloro-4'-fluoro-6'-methylphenyl)-4-methylaniline



3.08g (19.3mmol) of 2-chloro-4-fluoro-6-methyl-aniline (prepared from N-acetyl-4-fluoro-2-methylaniline by chlorination followed by hydrolyses), 3.48 g (20.3mmol) of 4-bromotoluene are dissolved in 55ml of toluene and after the addition of 3.43g (36mmol) of sodium tert-butoxide, 166mg (0.82mmol) of tri-tert-butylphosphin and 460mg (0.8mmol) of bis-dibenzylideneacetone-palladium(0), the mixture is heated with stirring under nitrogen to 90°C for 40 minutes. The usual aqueous acidic workup (50ml water, 10ml conc. HCl, 1g hyflo, filtration, washing the organic phase with water, drying, evaporation) gave 5.5g of the crude product which may be purified by flash-chromatography using silica and heptane as the eluent affording 3.52 g of N-(2'-chloro-4'-fluoro-6'-methylphenyl)-4-methylaniline as an oily substance.

¹H-NMR (400MHz, DMSO-d6): 2.18 (s, 3H, CH₃); 6.37 (d, 2H, H-C(2,6)]; 6.92 [d, 2H, H-C(3,5)]; 7.19 (dd, 1H, H-C(5')]; 7.32 (s, 1H, NH); 7.35 (dd, 1H, HC(3')].

Example 1d: N-(2'-Chloro-6'-methylphenyl)-4-methylaniline




1.02g (7.2mmol) of 2-chloro-6-methylaniline, 1.23g (7.2mmol) 4-bromotoluene, 1.15g (12mmol) sodium tert-butoxide, 160mg (0.7mmol) tri-tert-butylphosphine and 130mg (0.23mmol) bis-dibenzylideneacetone-palladium(0) are reacted in 50ml toluene under nitrogen at 90°C for 20 minutes and at 60°C over night. Aqueous workup (3N HCl, with hyflo, washing the organic phase with water) and flash-chromatography on silica using heptan/toluene (4:1) as the eluent affords 1.49g of N-(2'-chloro-6'-methylphenyl)-4-methylaniline.

¹H-NMR (400MHz, CDCl₃): 2.21 (s, 3H, C-6'-CH₃); 2.29 (s, 3H, C-4-CH₃); 5.61 (s,br, 1H, NH); 6.57 [d, 2H, HC(2,6)]; 7.04 [d, 2H, HC(3,5)]; 7.07 [t under signal at 7.04, 1H, HC(4')]; 7.16 [d, 2H, H(C5')]; 7.33 [d, 1H, H(C3')].

N,N-Bis-p-tolyl-2-chloro-6-methylaniline (9mg) is isolated as a byproduct.

Example 1e: N-(2'-Chloro-6'-methylphenyl)-4-ethylaniline




To a solution of 5.2 g (37mmol) of 2-chloro-6-methylaniline and 6.95 g (37.6 mmol) of 4-ethyl bromobenzene in 50ml of toluene is added 6.5 g (68 mmol) sodium tert-butoxide, 180 mg (0.89 mmol) tri-tert-butylphosphine (dissolved in 2 ml of toluene) and 300 mg (0.52 mmol) of bis-dibenzylideneacetone palladium(0). The mixture is heated under nitrogen to 90°C for 3 hours and then cooled to room temperature. Hyflo (1g), water (30ml) and conc. hydrochloric acid (10ml) are added and after stirring for 30 minutes the mixture is filtered. The organic phase is washed with water (30ml) twice and evaporated. The residue is subjected to flash-chromatography on silica (75g) eluting with heptane to afford 5.3g (21.6mmol, 58%) of N-(2'-chloro-6'-

methylphenyl)-4-ethylaniline as an almost colourless liquid.

¹H-NMR (300MHz, CDCl₃): 1.10 (t, 3H, CH₂-CH₂-); 2.10 [s, 3H, CH₃-C(6')]; 2.50 (q, 2H, CH₃-CH₂-); 5.54 (s, br, 1H, NH); 6.48 [d, 2H, HC(2,6)]; 6.93 [t, 1H, H(C4')]; 6.95 [d, 2H, HC(3,5)]; 7.05 [d, 1H, HC(5')]; 7.22 [d, 1H, HC(3')].

Example 1f: N-(2',4'-Dichloro-6'-methylphenyl)-4-ethylaniline




The mixture of 2,4-dichloro-6-methylaniline (3.313g, 18.8mmol), 4-ethyl bromobenzene (3.64g, 20mmol), sodium tert-butoxide (3.41g, 35mmol), racemic BINAP (0.274g, 0.44mmol), bis-dibenzylideneacetone-palladium(0) (250mg, 0.43mmol) and toluene (50ml) is refluxed under nitrogen for 22h. The mixture is cooled, treated with water (40ml), conc. HCl (10ml), hyflo (1.7g) stirred for additional 30minutes and filtered. The organic phase is washed with water twice and evaporated. The crude product (6.88g) is purified by flash-chromatography (silica, toluene) to afford 2.93 g of N-(2',4'-dichloro-6'-methylphenyl)-4-ethylaniline.

¹H-NMR (300MHz, CDCl₃): 1.15 (t, 3H, CH₂-CH₂-Ar); 2.08 (s, 3H, C-6'-CH₃); 2.50 (q, 2H, CH₃-CH₂-Ar); 5.42 (s, br., 1H, NH); 6.50 [d, 2H, HC(2,6,.)]; 6.96 [d, 2H, HC(3,5)]; 7.10 [s, 1H, HC(5')]; 7.25 [s, 1H, HC(3')].

The reaction proceeds much faster even at 85°C when BINAP is replaced by tri-tert-butylphosphine; however N,N-di-(4-ethylphenyl)-2',4'-dichloro-6'-methylaniline is formed as a byproduct in considerable amounts when excess of 4-ethyl bromobenzene is used. This byproduct can be isolated as a solid, mp: 74-75°C; ¹H-NMR (400MHz, CDCl₃): 1.24 (t, 6H, CH₂-CH₃); 2.09 (s, 3H, C-6'-CH₃); 2.61 (q, 4H, CH₂-CH₃); 6.89 [d, 4H, HC(2,6)]; 7.06 [d, 4H, HC(3,5)]; 7.20 [s, 1H, HC(5')]; 7.36 [s, 1H, HC(3')]; MS: 383 (M⁺), 368 (M-CH₃), 354 (M-CH₂CH₃).


Example 2: N-(2',3',6'-Trifluorophenyl)-4-ethylaniline



To a solution of 1.21g of 4-ethylaniline, 1.10g of 2,3,6-trifluoro-bromobenzene in 10g of toluene is added consecutively 350 mg BINAP and 300 mg of bis-dibenzylideneaceton-palladium (0) [Pd(dba)₂] in 3 ml of toluene and 0.9 g of sodium tert.-butoxide in 3 ml toluene. The mixture is flushed with nitrogen and heated for 6 h under reflux. After cooling to room temperature, water (30 ml), concentrated hydrochloric acid (10 ml) and hyflo (1 g) are added and stirring is continued for 1 h. The mixture is filtered and the filtrate is separated into its phases. The organic phase is washed three times with water, dried using magnesium sulfate and evaporated to dryness. The residue can be used as such in the following step or purified by flash chromatography on silica using toluene as the eluent affording 1.13 g of N-(2',3',6'-trifluorophenyl)-4-ethylaniline.

¹H-NMR (300MHz, CDCl₃): 1.14 (t, 7.7Hz, 3H, CH₂-CH₂-Ar); 2.53(q, 7.7Hz, 2H, CH₃-CH₂-Ar); 5.29 (br. s, 1H, NH); 6.7-6.81 [m, 2H, C-4'-H, HC(5')]; 6.75 [d, 2H, HC(2,6)]; 7.02 [d, 8.5Hz, 2H, HC(3,5)].

Diphenylamine compounds of Formula VIII, for instance as prepared above in Examples 1 and 2, are converted to the corresponding compounds of Formula VII




as described in Example 3

Example 3a


N-(2',3',4',6'-Tetrafluorophenyl)-N-chloroacetyl-4-

methylaniline



The mixture of N-(2',3',4',6'-tetrafluorophenyl)-4-methylanilin (0.82g, 3.2 mmol) and chloro acetylchloride (1.6g) is heated with stirring to 90°C under nitrogen for 1.3 h. To destroy excess of the acid chloride, 2-propanol and water (2 ml each) is added and stirring is continued over night at room temperature. After adding toluene (20ml), the mixture is extracted with sodium bicarbonate and the organic phase is dried with magnesium sulfate and evaporated to dryness. The residue is purified by flash chromatography (silica, toluene) to obtain N-(2',3',4',6'-tetrafluorophenyl)-N-chloroacetyl-4-methylaniline (0.98g, 2.95mmol) as an oil.


Example 3b: N-(2',3',5',6'-Tetrafluorophenyl)-N-chloroacetyl-4-ethylaniline



N-(2',3',5',6'-tetrafluorophenyl)-4-ethylanilin (2.05g) and chloro acetylchloride (1.99g) is mixed without solvent and heated with stirring to 90°C under nitrogen for 20 h. Tetrahydrofuran (10ml) and aqueous sodium bicarbonate are added after cooling and stirring is continued for about 1 hour. The organic phase is diluted with toluene and washed with water three times and dried over magnesium sulfate. Evaporation and chromatography of the residue (silica, toluene) gave N-(2',3',5',6'-tetrafluorophenyl)-N-chloroacetyl-4-ethylaniline (1.84g) as a solid which is recrystallised from heptane, mp.: 72°C

¹H-NMR (400MHz, DMF-d7, 140°C): 1.25 (t, 3H, CH₃); 2.70 (q, 2H, CH₂); 4.28 (s, 2H, CH₂-CO); 7.35 [d, 2H, HC(3,5)]; 7.43 [d, 2H, HC(2,6)]; 7.65 [tt, 1H, HC(4')].


Example 3c: N-(2'-Chloro-4'-fluoro-6'-methylphenyl)-N-chloroacetyl-4-methylaniline



1.32g of N-(2'-Chloro-4'-fluoro-6'-methylphenyl)-4-methylaniline is reacted with chloroacetylchloride (1.76g) at 90°C for 30minutes. The cooled mixture is stirred with toluene (20ml) and aqu. sodium carbonate for 30 minutes and the organic phase is evaporated. The residue is purified flash-chromatography on silica using toluene affording 1.04g of N-(2'-chloro-4'-fluoro-6'-methylphenyl)-N-chloroacetyl-4-methylaniline as a solid which is recrystallised from heptane/2-propanol (9:1), mp.: 96-97°C.

¹H-NMR (400MHz, DMF-d7, 120°C, all peaks appear broadend or split): 2.43 (s, 3H, CH₃); 4.31 (s, 2H, Cl-CH₂-CO); 7.31 [d, 1H, HC(5')]; 7.32 and 7.40 [AB, 4H, C-HC(2,6) and HC(3,5)]; 7.45 [s, 1H, HC(3')].

Example 3d: N-(2'-Chloro-6'-methylphenyl)-N-chloroacetyl-4-methylaniline




The solution of N-(2'-chloro-6'-methylphenyl)-4-methylaniline (1.4g) in 2.21g chloroacetylchloride is heated to 90°C for 4 h. The mixture is diluted with toluene (25ml), cooled to room temperature and washed with aqu. sodium carbonate. The organic phase is dried, evaporated and the residue is subjected to flash chromatography [57g silica, toluene and toluene/ethylacetate (98:2)] to afford 1.45g of N-(2'-Chloro-6'-methylphenyl)-N-chloroacetyl-4-methylaniline which is crystallised from heptane,

mp: 113-114°C.

Example 3e:

N-(2'-Chloro-6'-methylphenyl)-N-chloroacetyl-4-ethylaniline




N-(2'-Chloro-6'-methylphenyl)-N-4-ethylaniline (4.95 g, 20 mmol) is treated with chloro acetylchloride (3.23 g, 28.5 mmol) and the mixture is heated with stirring under nitrogen at 95°C for 40 minutes. After adding 2-propanol (5 ml) and cooling to room temperature, the mixture is diluted with toluene and extracted with aqu. sodium bicarbonate. The organic phase is washed with water and evaporated to dryness. Flash chromatography on silica (55g) using toluene as the eluent affords 5.66 g (17.6mmol, 88%) of N-(2'-chloro-6'-methylphenyl)-N-chloroacetyl-4-ethylaniline as a viscous liquid.

¹H-NMR (400MHz, DMF-d7, 140°C): 1.22 (t, 3H, CH₂-CH₂-), 2.32 (s, 3H, CH₃-C₆'); 2.65 (q, 2H, CH₃-CH₂-); 4.12, 4.18 (AB, 2H, CH₂-Cl); 7.22 and 7.31 [each d, each 2H, HC(2,6) and HC(3,5)]; 7.3-7.5 [m, 3H, HC(3',4',5')].

Example 3f:

N-(2',4'Dichloro-6'-methylphenyl)-N-chloroacetyl-4-

ethylaniline




N-(2',4'Dichloro-6'-methylphenyl)-4-ethylaniline (4.83g as a mixture with the byproduct N,N-di-(4-ethylphenyl)-2',4'-dichloro-6'-methylaniline) is dissolved in 4.18g of chloro acetylchlorid and heated to 100°C for 1.5h. The mixture is cooled, diluted with toluene (50ml) and extracted with aqu. sodium bicarbonate. The organic

phase is evaporated to dryness and chromatographed on silica (75g) eluting with toluene to afford unreacted N,N-di-(4-ethylphenyl)-2',4'-dichloro-6'-methylaniline and N-(2',4'-dichloro-6'-methylphenyl)-N-chloroacetyl-4-ethylaniline (2.95g). A crystallised sample melts at 83-84°C.


¹H-NMR (400MHz, DMF-d7, 140°C): 1.22 (t, 3H, CH₃-CH₂); 2.31 (s, 3H, C-6'-CH₃); 2.56 (q, 2H, CH₃-CH₂); 4.20 (s, split, 2H, Cl-CH₂-CO); 7.35, 7.42 [AB, 4H, HC(2,6) and HC(3,5) respectively]; 7.40 [s, br. 1H, HC(5')], 7.53 [s, br, 1H, HC(3')].

Alternatively compounds of Formula VIII may be prepared by a procedure involving coupling of 1-methoxy-4-methylcyclohexa-1,4-diene or 1-methoxy-4-ethylcyclohexa-1,4-diene with an aniline derivative of formula IV as defined above to give an intermediate compound of Formula XIII (or tautomer thereof)



which is oxidised without isolation to give the compound of Formula VIII, as described below in Example 4.

Example 4a): N-(2',6'-Dichlorophenyl)-4-methylaniline




a) A solution of 4.35 g 2,6-dichloro-aniline in 4 ml of tetrahydrofuran and 35 ml of chlorobenzene is cooled down to -40 to -45°C. At this temperature, 5.09 g of titanium-tetrachloride is added to the solution, followed by the addition of 5.0 g of 1-Methoxy-4-methylcyclohexa-1,4-diene. The reaction mixture is allowed to warm up to approximately -35°C and stirred for 2 hours at this temperature. A solution of 10.18 g of iodine in 20 ml of tetrahydrofuran and 2.3 ml of acetic acid is then added dropwise to the reaction mixture and the temperature was allowed to warm up to 0°C. The mixture was stirred for 1 hour at 0°C and 16 hours at 25°C. Then 3.4 g of iodine is added to the reaction mixture and stirring is continued for additional 24 hours at 25°C. The reaction is finally quenched by pouring the reaction mixture onto a mixture of 250 ml of aqueous Sodium bisulfite (38-40%) and 400 ml of saturated aqueous sodium carbonate. The water phase is extracted with ethyl acetate (1x200 ml and 2x100 ml), the ethyl acetate phases are unified and washed with 100 ml of water. The organic phase was dried over anhydrous sodium sulfate and evaporated in vacuo to yield 11.44 g of a dark slurry. The slurry was dissolved in hexane/t-butyl-methylether and the solution was filtered over silica gel to obtain, after evaporation of the solvent, 5.75 g of crude product. The product can be used directly in the next step. Alternatively, it can be purified e.g. by column chromatography on silica gel with hexane/t-butyl-methylether (9:1) as eluent to yield pure N-(2',6'-Dichlorophenyl)-4-methylaniline.

¹H-NMR(CDCl₃, 400 MHz, 300K) δ 2.31(s, 3H, CH₃), 3.6-4.8(broad signal, 1H, NH), 6.68(d, J= 8 Hz, 2H, H-C(2) and H-C(6)), 7.02-7.12 (m, 3H, H-C(3), H-C(5) and H-C(4')), 7.38 (d, J= 8 Hz, 2H, H-C(3') and H-C(5')).

MS(EI): m/z 251(M⁺), 216(M-Cl)⁺, 181(M-2Cl)⁺

Example 4b): N-(2'-Chloro-6'-fluoro-phenyl)-4-methylaniline




A solution of 3.91 g 2-chloro-6-fluoro-aniline in 4 ml of tetrahydrofuran and 35 ml of chlorobenzene is cooled down to -40 to -45°C. At this temperature, 5.09 g of titanium-tetrachloride is added to the solution, followed by the addition of 5.0 g of 1-Methoxy-4-methylcyclohexa-1,4-diene. The reaction mixture is allowed to warm up to approx. -35°C and stirred for 2 hours at this temperature. A solution of 10.18 g of iodine in 20 ml of tetrahydrofuran and 2.3 ml of acetic acid is then added drop-wise to the reaction mixture and the temperature was allowed to warm up to 0°C. The mixture was stirred for 1 hour at 0°C and 16 hours at 25°C. Then 3.4 g of iodine is added to the reaction mixture and stirring is continued for additional 24 hours at 25°C. The reaction is finally quenched by pouring the reaction mixture onto a mixture of 250 ml of aq. Sodium bisulfite (38-40%) and 400 ml of saturated aq. sodium carbonate. The aqueous phase is extracted with ethyl acetate (1x200 ml and 2x100 ml), the ethyl acetate phases are unified and washed with 100 ml of water. The organic phase was dried over anhydrous sodium sulfate and evaporated in vacuo to give a yellow viscous liquid. The liquid was dissolved in hexane/t-butyl-methylether and the solution was filtered over silica gel to obtain, after evaporation of the solvent, 4.33 g of crude product. The product can be used directly in the next step. Alternatively, it can be purified e.g. by column chromatography on silica gel with hexane / t-butyl-methylether (9:1) as eluent to yield pure N-(2'-Chloro-6'-fluoro-phenyl)-4-methylaniline.

¹H-NMR (DMSO-d⁶, 500 MHz, 300K) δ 2.17(s, 3H, CH₃); 6.53[dd, J = 8.5Hz, J_{H-F} = 1.5Hz, 2H, HC(2) and HC(6)], 6.94[d, J = 8.0Hz, 2H, HC(3) and HC(5)],

7.16[ddd, $J = 8.0\text{Hz}$, $J_{\text{H-F}} = 6.0\text{Hz}$, 1H, HC(4')], 7.25[ddd, $J = 8.0, 1.5\text{Hz}$, $J_{\text{H-F}} = 8.0$, 1H, HC(5')]; 7.34[ddd, $J = 8.0, 1.5\text{Hz}$, $J_{\text{H-F}} = 1.5$, 1H, HC(3')]; 7.63(s, 1H, NH).

MS(EI) m/z 235 (100, M^+), 200 (35, $(\text{M}-\text{Cl})^+$), 185 (55)

Example 4c): N-(2'-Chloro-6'-methyl-phenyl)-4-ethylaniline



A solution of 3.0 g 2-Chloro-6-methyl-aniline in 3.5 ml of tetrahydrofuran and 31 ml of chlorobenzene is cooled down to -40 to -45°C. At this temperature, 4.01 g of titanium-tetrachloride is added to the solution, followed by the addition of 6.18 g of 1-Methoxy-4-ethylcyclohexa-1,4-diene. The reaction mixture is allowed to warm up to approx. -35°C and stirred for 3 hours at this temperature. A solution of 8.06 g of iodine in 16.4 ml of tetrahydrofuran and 1.8 ml of acetic acid is added to the reaction mixture and the temperature is allowed to warm up to 0°C. The mixture is stirred for 30 minutes at 0°C and 2 hours at 25°C. Then 2.68 g of iodine is added to the reaction mixture and stirring is continued for additional 24 hours at 25°C. Again, 2.68 g of iodine is added and stirring is continued for additional 72 hours at 25°C. The reaction is finally quenched by pouring the reaction mixture onto a mixture of 250 ml of aqueous sodium bisulfite (38-40%) and 450 ml of saturated aqueous sodium carbonate. The water phase is extracted with ethyl acetate (1x200 ml and 2x100 ml), the ethyl acetate phases are unified and washed with 100 ml of brine. The organic phase was dried over anhydrous

sodium sulfate and evaporated in vacuo to give a dark viscous liquid. The liquid was dissolved in heptane / toluene and the solution was filtered over silicagel to obtain, after evaporation of the solvent, 2.0 g of crude product. The product can be used directly in the next step. Alternatively, it can be purified e.g. by column chromatography on silica gel with heptane / toluene (7:3) as eluent to yield pure N-(2'-Chloro-6'-methyl-phenyl)-4-ethylaniline.

¹H-NMR(CDCl₃, 400 MHz, 300K) δ 1.24 (t, J= 7.5 Hz, 3H, H₃C(8)), 2.22 (s, 3H, H₃C-C(2')), 2.61 (q, J= 7.5 Hz, 2H, H₂C(7)), 4.0-5.5 (broad signal, 1H, NH), 6.60 (d-like, J= 8 Hz, 2H, H-C(2) and H-C(6)), 7.02-7.10 (m, 3H, H-C(3), H-C(5) and H-C(4')), 7.10-7.20 (m, 1H, H-C(3')), 7.33 (d-like, J= 9 Hz, 1H, H-C(5')).

MS: m/z 245(M⁺), 230, 214, 194, 180.

The 1-Methoxy-4-methylcyclohexa-1,4-diene and 1-Methoxy-4-ethylcyclohexa-1,4-diene starting materials for Example 4 are prepared according to a known literature procedure.

1-Methoxy-4-methylcyclohexa-1,4-diene (



Preparation according to a known literature procedure:

G.S.R. Subba Rao, D. K. Banerjee, L. Uma Devi and Uma Sheriff,

Australian Journal of Chemistry 1992, 45, p. 187-203


1-Methoxy-4-ethylcyclohexa-1,4-diene



Compound 4 was prepared according to the same literature procedure given above for 1-methoxy-4-methylcyclohexa-1,4-diene.


The products of Examples 4 are converted into the corresponding compounds of Formula VII for instance as described in Examples 3 above and 5 below

Example 5: N-(2',6'-Dichlorophenyl)-N-chloroacetyl-4-methylaniline



N-(2',6'-Dichlorophenyl)-4-methylaniline (4.86g) is reacted with chloroacetylchloride (3.92g) at 90°C for 2h. After dilution with toluene, the mixture is washed with aqueous sodiumcarbonate twice, 40% aqu. sodium bisulfite and water. The organic phase is dried (MgSO4) and evaporated. The residue is recrystallised from ethanol (12g) to obtain N-(2',6'-Dichlorophenyl)-N-chloroacetyl-4-methylaniline (2.83g), mp: 129.5-130°C.


In a yet further alternative compounds of Formula VII may be prepared by a procedure involving a Smiles type rearrangement of a compound of Formula IX



to give an intermediate product of Formula VIII as defined above which is converted without being isolated to the compound of Formula VII as described in Example below.

Example 6a):

N-(2',6'-dichloro-4'-methylphenyl)-N-chloroacetyl-4-methylaniline



12g (67 mmol) of 2,6-dichloro-4-methylphenol are dissolved in 25 ml of 2-propanol followed by the addition of 10.5g (76 mmol) of potassium carbonate and 12.8g (70 mmol) of 2-chloro-N-(4-methylphenyl)acetamide. The mixture is refluxed for 4h. At this time, the formation of A: 2-(2',6'-dichloro-4'-methylphenoxy)-N-(4-methylphenyl)acetamide is completed. 13.6ml of sodium methylate solution 30% in methanol are slowly added and the temperature is increased to about 85°C by distilling 25ml of solvent. The mixture is stirred 2h more to complete the formation of B. 25ml of water are added at 70°C to obtain a 2 phases solution. The lower layer is

discarded. The upper layer is diluted with 20 ml of heptane-fraction and washed with 2x 20 ml of water. The organic phase is separated and concentrated in vacuo to obtain N-(2',6'-dichloro-4'-methylphenyl)-4-methylaniline as a crude oil. GC/MS: 265(100,M⁺), 195(130).

This oil is heated to 90°C and treated with 6.5ml of chloroacetylchloride. After 2h the mixture is diluted with 60ml of 2-propanol, cooled to about 20°C and seeded. The precipitated suspension is cooled to 0°C. The crystals are isolated by filtration, washed with cold 2-propanol and dried to obtain N-(2',6'-dichloro-4'-methylphenyl)-N-chloroacetyl-4-methylaniline. Mp: 140-141°C.

¹H-NMR (DMF-d7, 413K, 400Mz) 2.33 (s, 3H, CH₃); 2.40(s, 3H, CH₃); 4.18(s, 2H, CH₂); 7.22[d, 2H, HC(5) and HC(3)]; 7.38[d, 2H, HC(2) and HC(6)]; 7.42[s, 2H, HC(3')and HC(5')].

Example 6b): N-(2'-chloro-6'-fluorophenyl)-N-chloroacetyl-4-methylaniline

Same procedure as example 6a, starting from 2-chloro-6-fluorophenol

Mp: 80-82°C.

¹H-NMR (DMF-d7, 393K, 400Mz) 2.4(s, 3H, CH₃); 4.3(s, 2H, CH₂); 7.35[d, 2H, HC(3) and HC(5)]; 7.43[ddd, 1H, HC(5')]; 7.48[d, 2H, HC(2) and HC(6)]; 7.55[d, 1H, HC(3')]; 7.6[ddd, 1H, HC(4')].

Example 6c): N-(2',3',6'-trifluorophenyl)-N-chloroacetyl-4-ethylaniline

Same procedure as example 6a, starting from 2,3,6-trifluorophenol and 2-chloro-N-(4-ethylphenyl)acetamide. The crude intermediate N-(2',3',6'-trifluorophenyl)-4-ethylaniline was roughly purified by filtration on silica using toluene as eluent.

Mp: 49-50°C. ¹H-NMR(DMF-d7, 413K, 400MHz) 1.24(t, 3H, CH₃); 2.70(q, 2H, CH₂-CH₃); 4.25(s, 2H, CH₂-Cl); 7.20[m, 1H, HC(5')]; 7.34[d, 2H, HC(3) and HC(5)]; 7.42[d, 2H, HC(2) and HC(6)]; 7.46[m, 1H, HC(4')].

Example 6d): N-(2'-chloro-6'-fluorophenyl)-N-chloroacetyl-4-ethylaniline

Same procedure as example 6a starting from 2-chloro-6-fluorophenol and 2-chloro-N-

(4-ethylphenyl)acetamide.


Mp: 67-68°C. $^1\text{H-NMR}$ (DMF-d7, 413K, 500MHz) 1.23(t, 3H, CH_3); 2.68(q, 2H, $\text{CH}_2\text{-CH}_3$); 4.20(s, 2H, $\text{CH}_2\text{-Cl}$); 7.29[d, 2H, $\text{HC}(3)$ and $\text{HC}(5)$]; 7.34[m, 1H, $\text{HC}(5')$]; 7.43[d, 2H, $\text{HC}(2)$ and $\text{HC}(6)$]; 7.48[m, 2H, $\text{HC}(3')$ and $\text{HC}(4')$].

Example 6e): N-(2',6'-dichlorophenyl)-N-chloroacetyl-4-methylaniline

Same procedure as example 6a starting from 2,6-dichlorophenol and 2-chloro-N-(4-methylphenyl)acetamide. At the end of the acetylation reaction the mixture was diluted with a small amount of toluene (0.2 part) to prevent solidification.


Mp: 129-130°C. $^1\text{H-NMR}$ (DMF-d7, 393K, 500Mz) 2.40(s, 3H, CH_3); 4.28(s, 2H, $\text{CH}_2\text{-Cl}$); 7.30[d, 2H, $\text{HC}(3)$ and $\text{HC}(5)$]; 7.46[d, 2H, $\text{HC}(2)$ and $\text{HC}(6)$]; 7.54[m, 1H, $\text{HC}(4')$]; 7.67[d, 2H, $\text{HC}(3')$ and $\text{HC}(5')$].

Compounds of Formula VII are cyclised to give lactams of Formula II



as described in Example 7

Example 7a): N-(2',6'-dichloro-4'-methylphenyl)-5-methyloxindole



A mixture of 6.85g (20 mmol) of N-(2',6'-dichloro-4'-methylphenyl)-N-chloroacetyl-4-methylaniline and 3.36g (26 mmol) of aluminium chloride was heated slowly to 160-170°C and held at this temperature for 3-4h. During this time, nitrogen was continuously bubbled into the melt. The mixture was diluted with 20 ml of toluene and added on 20 ml of warm water. The organic layer was separated, washed with water and evaporated. The residue was crystallised from 20 ml of 2-propanol giving N-(2',6'-dichloro-4'-methylphenyl)-5-methyloxindole. Mp:153-154°C.

¹H-NMR (DMSO-d6, 500Mz, 300K) 2.29 [s, 3H, CH₃-C(5)]; 2.41[s, 3H, CH₃-C(4')]; 3.81(s, 2H, CH₂); 6.27 [d, 1H, HC(7)]; 7.00 [d, 1H, HC(6)]; 7.19 [s, 1H, HC(4)]; 7.58 [s, 2H, HC(3') and HC(5')].

Example 7b): N-(2'-chloro-6'-fluorophenyl)-5-methyloxindole

Same procedure as example 7a

Mp:137-138°C. ¹H-NMR (DMSO-d6, 500MHz, 300K) 2.27(s, 3H, CH₃); 3.83(s, 2H, CH₂) 6.35[d, 1H, HC(7)]; 7.01[d, 1H, HC(6)]; 7.19 [s, 1H, HC(4)]; 7.52 [d, 1H, HC(5')]; 7.60 [d, 1H, HC(3')], 7.63 [d, 1H, HC(4')].

Example 7c): N-(2',3',6'-trifluorophenyl)-5-ethyloxindole

Same procedure as example 7a. After 4h reaction, 10% more aluminium chloride was added . Overall reaction time: 6h.

Mp: 171-172°C. ¹H-NMR (DMSO-d6, 500Mz, 300K) 1.18 (t, 3H, CH₃); 2.60[q, 2H, CH₂-CH₃]; 3.89[s, 2H, CH₂-CO]; 6.62 [d, 1H, HC(7)]; 7.09[d, 1H, HC(6)]; 7.25 [s, 1H, HC(4)]; 7.46 [m, 1H, HC(5')]; 7.76 [m, 1H, HC(4')].

Example 7d): N-(2'-chloro-6'-fluorophenyl)-5-ethyloxindole


Same procedure as example7c.

Mp: 129-130°C. ¹H-NMR (DMSO- d6, 300K, 500Mz) 1.18 (t, 3H, CH₃); 2.59 [q, 2H, CH₂-CH₃]; 3.86 (s, 2H, CH₂-CO); 6.39 [d, 1H, HC(7)]; 7.05 [d, 1H, HC(6)]; 7.24 [s, 1H, HC(4)], 7.59 [m, 1H, HC(5')]; 7.64 [m, 2H, HC(3') and HC(4')].

Example 7e): N-(2',6'-dichlorophenyl)-5-methyloxindole


Same procedure as 7a

¹H-NMR (DMSO-d6, 500MHz, 300K) 2.30 (s, 3H, CH₃); 3.85 (s, 2H, CH₂); 6.29 [d, 1H, HC(7)]; 7.02 [d, 1H, HC(6)]; 7.22 [s, 1H, HC(4)], 7.62 [t, 1H, HC(4')]; 7.76 [d, 2H, HC(3') and HC(5')].

Example 7f): N-(2',3',4',6'-Tetrafluorophenyl)-5-methyloxindole

The solution of N-(2',3',4',6'-tetrafluorophenyl)-N-chloroacetyl-4-methylaniline (0.97g, 2.97mmol) in chlorobenzene (2.5g) is treated with aluminum trichloride (1.05g, 7.8mmol) and the mixture is heated with stirring in an oil bath (155°C) for 5h while flushing the flask with nitrogen. Toluene (30ml) and water (20ml) are added and stirring is continued for 30 minutes at room temperature. The phases are separated and the organic phase is washed with hydrochloric acid (2N) and water. Evaporation under reduced pressure affords a solid (0.84g, 2.85mmol) which is recrystallised from 2-propanol to afford pure N-(2',3',4',6'-tetrafluorophenyl)-5-methyloxindole, mp. 172-173°C.


¹H-NMR (300MHz, 300K, CDCl₃): 2.28 (s, 3H, CH₃); 3.65 [s, 2H, H₂C(3)]; 6.39 [d, 7.5Hz, 1H, HC(7)]; 6.85-7.0 [m, 1H, HC(5')]; 6.98 üd, 7.5Hz, 1H, HC(6)]; 7.09 [s, 1H, HC(4)].

Example 7 g): N-(2'-Chloro-6'-methylphenyl)-5-ethyloxindole

In a flask are mixed N-(2'-chloro-6'-methylphenyl)-N-chloroacetyl-4-ethylaniline (2.08g) are mixed with aluminum trichloride (1.16g) and the mixture is flushed with nitrogen. The flask is introduced into an oil bath (155-160°C) and the mixture is stirred under a stream of nitrogen for 4.5 hours. The mixture is slightly cooled to about 100°C, treated with toluene (30ml) and 1N HCl (20ml) and stirred for 30 minutes while the temperature decreases gradually. After phase separation, the organic phase is washed with 1N HCl and water, dried (magnesium sulfate) and evaporated. The residue is chromatographed on silica (86g) using toluene containing 5-20% isopropyl acetate as eluent affording the title product.


Mp: 125-126°C

In a yet further alternative lactams of Formula II are prepared by oxidation of an unsaturated lactam of Formula III



which may be prepared, for instance as described in Example 8.

Example 8: (5-Ethyl-2-morpholin-4-yl-cyclohex-2-enylidene)-acetic acid ethyl ester



91.6 g of 4-Ethyl-cyclohexanone, 73.6 g of morpholine and 2 g of *p*-toluene-sulfonic acid monohydrate are dissolved in 400 ml of toluene. The mixture is heated to reflux and the water formed is removed by a water separator. After reacting for about 24h, the reaction mixture is cooled to 100°C and 2 g of *p*-toluene-sulfonic acid are added, followed by the addition of 157.22 g of glyoxylic acid ethyl ester during 30 minutes. The mixture is again heated to reflux for 5 hours and allowed to cool down to 22°C. The solvent is evaporated in vacuo and the crude product is distilled in vacuo at 140-150°C / 9.5⁻² mbar.


¹H-NMR(CDCl₃, 500 MHz, 277K) δ 0.896 ppm (t, J= 7 Hz, 3H, H₃C(17)), 1.277 (t, J= 7 Hz, 3H, H₃C(10)), 1.20-1.45 (m, 2H, H₂C(16)), 1.50-1.62 (m, 1H, H-C(4)), 1.876 (ddd, J₁= 18 Hz, J₂= 9 Hz, J₃= 3 Hz, 1H, H-C(3)), 2.13 (m, 1H, H-C(5)), 2.35

(dt, $J_1 = 17$ Hz, $J_2 = 5$ Hz, 1H, H-C(3)), 2.55-2.65 (m, 2H, H-C(12) and H-C(15)), 2.72-2.80 (m, 2H, H-C(12) and H-C(15)), 3.55 (dm, $J = 15$ Hz, 1H, H-C(5)), 3.74 (m, 4H, H₂C(13) and H₂C(14)), 4.152 (q, $J = 7$ Hz, 2H, H₂C(9)), 5.46 (dd, $J_1 = 5$ Hz, $J_2 = 3$ Hz, 1H, H-C(2)), 6.17 (broad s, 1H, H-C(7)). Assignments according to numbers given on the formula.

IR(film): strong absorptions at 2960, 1710, 1624, 1609, 1191, 1156 and 1120 cm⁻¹.

MS(EI): m/z 279(M⁺), 250(M-C₂H₅)⁺, 234, 206(M-CO₂C₂H₅)⁺, 176, 164, 135, 84.

b). Synthesis of (5-Ethyl-2-oxo-cyclohexylidene)-acetic acid ethyl ester




10 g of [5-Ethyl-2-morpholin-4-yl-cyclohex-2-enylidene]-acetic acid ethyl ester are dissolved in 20 ml of toluene. 12 ml of 6M HCl are added dropwise under rigorous stirring and the reaction mixture is stirred for additional 60 minutes at 22°C. The organic layer is separated and washed with 25 ml of water twice. The combined water layers are extracted with 25 ml of toluene. The combined toluene layers are dried over anhydrous sodium sulfate and the solvent is evaporated in vacuo to yield 6.72 g of [5-ethyl-2-oxo-cyclohexylidene]-acetic acid ethyl ester as an oil.

¹H-NMR (CDCl₃, 500MHz, 277K) δ 0.935 ppm (t, $J = 7$ Hz, 3H, H₃C(12)), 1.259 (t, $J = 7$ Hz, 3H, H₃C(10)), 1.31-1.45 (m, 2H, H₂C(11)), 1.46-1.55 (m, 1H, H-C(5)), 1.59-1.69 (m, 1H, H-C(4)), 1.97-2.04 (m, 1H, H-C(5)), 2.296 (ddd, $J = 17$ Hz, 11 Hz and 3Hz, 1H, H-C(3)), 2.383 (m, 1H, H-C(6)), 2.615 (dt, $J = 17$ and 4 Hz, 1H, H-C(6)), 3.57 (dm, $J = 17$ Hz, 1H, H-C(3)), 4.17 (q, $J = 7$ Hz, 2H, H₂C(9)), 6.42 (m, 1H, H-C(7)). Assignments according to numbers given on the formula.

IR(film): strong absorptions at 1719, 1698 and 1200 cm⁻¹.

MS (EI): m/z 210(M⁺), 164(M-C₂H₅OH)⁺, 135.

c). Synthesis of 1-(2-Chloro-6-methyl-phenyl)-5-ethyl-1,4,5,6-tetrahydro-indol-2-one



3.45 g of 2-Chloro-6-methyl-aniline are dissolved in 26 ml of toluene. 0.227 g of p-toluene-sulfonic acid (mono hydrate) are added and the mixture is heated to reflux. A solution of 5.0 g of (5-Ethyl-2-oxo-cyclohexylidene)-acetic acid ethyl ester in 13 ml of toluene is added drop-wise during 75 minutes and the water formed is collected by the means of a water separator. The reaction mixture is heated to reflux for 15 hours, during which time the condensing solvent is frequently removed and replaced by fresh toluene. For work-up, the mixture is cooled to 22°C and is treated with 70 ml of saturated aqueous sodium bicarbonate solution under rigorous stirring. The layers are separated and the toluene phase is washed with a 5% aqueous solution of citric acid and finally with a 10% solution of sodium chloride in water. The aqueous phases are extracted with 70 ml of toluene and the toluene phases are combined. The solvent is evaporated in vacuo to yield 7.1 g of the crude product as a highly viscous oil. An analytical sample of the crude product can be purified by chromatography on silica gel using toluene/ethyl acetate (9:1) as eluent to yield pure 1-(2-Chloro-6-methyl-phenyl)-5-ethyl-1,4,5,6-tetrahydro-indol-2-one.


¹H-NMR (d₆-DMSO, 400MHz, 300K) δ 0.894 ppm (t, J= 7Hz, 3H, H₃C(11)), 1.34-1.43 (m, 2H, H₂C(10)), 1.70-1.82 (m, 1H, H-C(5)), 1.90-2.02 (m, 1H, H-C(6)), 2.038 (s, 3H, H₃C(6')), 2.28-2.40 (m, 2H, H-C(4) and H-C(6)), 2.87 (dd, J₁= 17Hz and J₂= 4 Hz, 1H, H-C(4)), 5.14 (m, 1H, H-C(7)), 5.96 (broad s, 1H, H-C(3)), 7.3-7.5 (m, 3H, H-C(3'), H-C(4'), H-C(5')). Assignments according to the numbers given on the

formula.

IR (film): strong absorptions at 1703, 1660 and 1476 cm⁻¹.

MS (EI): m/z 287 (M⁺), 272 (M-CH₃)⁺, 258 (M-C₂H₅)⁺, 252 (M-Cl)⁺.

d): Synthesis of N-(2-Chloro-6-methyl-phenyl)-5-ethyl-oxindole




1-(2-Chloro-6-methyl-phenyl)-5-ethyl-1,4,5,6-tetrahydro-indol-2-one can be oxidized by classical methods, e.g. with 10% Pd-C in refluxing xylene to yield N-(2-Chloro-6-methyl-phenyl)-5-ethyl-oxindole.

¹H-NMR and MS spectra see example 7g.

Lactams of Formula II as defined above are converted to compounds of Formula I as defined above, for instance as described in Example 9 below.

Example 9 a): 5-Methyl-2-(2',6'-dichloro-4'-methylanilino)phenylacetic acid



A mixture of 1.5g of N-(2',6'-dichloro-4'-methylphenyl)-5-methyloxindole, 18ml of ethanol and 1ml of water is heated to reflux. 1.9g of a 30% sodium hydroxide solution is slowly added and reflux is continued for 4-5h. The solution is cooled to about 40°C and treated slowly with a solution of 1.5g of concentrated hydrochloric acid in 12ml of water up to a pH of 3-4. The obtained suspension is cooled to 20°C. The crystals are collected by filtration, washed with water and dried giving 5-Methyl-2-(2',6'-dichloro-4'-methylanilino)phenylacetic acid.


Mp: 179-182°C. ¹H-NMR (DMSO-d6, 300K, 500Mz) 2.22[s, 3H, CH₃-C(5)]; 2.32[s, 3H, CH₃-C(4')]; 3.67(s, 2H, CH₂); 6.18[d, 1H, HC(3)], 6.87[s, d, 1H, HC(4)]; 6.97(s, 1H, NH); 7.02[s, 1H, HC(6)]; 7.36[s, 2H, HC(3') and HC(5')]; 12.68(br.s, 1H, COOH).

Example 9b): 5-Methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid

Same procedure as 9a.

Mp: 152-154°C ¹H-NMR(DMSO-d6, 500MHz, 300K) δ 2.21(s, 3H, CH₃), 3.64(s, 2H, CH₂); 6.42[dd, 1H, HC(3)], 6.90[dd, 1H, HC(4)], 7.01[d, 1H, HC(6)], 7.09(s, 1H, NH), 7.09[ddd, 1H, HC(4')], 7.23[ddd, 1H, HC(5')], 7.34[ddd, 1H, HC(3')], 12.67(s, 1H, COOH).

Example 9c): 5-Methyl-2-(2',3',4',6'-tetrafluoroanilino)-phenylacetic acid



The suspension of 350 mg of N-(2',3',4',6'-tetrafluorophenyl)-5-methyloxindole in 20ml of ethanol and 5 ml of water is degassed by passing through nitrogen for 1.5h. Then 260mg of 30% aqueous sodium hydroxide is added and the mixture is heated to reflux for 6.5 hours. Most of the ethanol is then removed by distillation the mixture is cooled to room temperature followed by the slow addition of 1N hydrochloric acid


(1.05g) to reach a pH of about 3. The precipitate is then filtered, washed with ethanol/water (1:1) and dried in vacuo at room temperature affording the title product. Mp: 145-146°C.

¹H-NMR (300MHz, DMSO-d6): 2.23 (s, 3H, CH3); 3.65 (s, 2H, CH₂-COO); 6.55 [s, 1H, HC(3)]; 6.92 [d, 1H, HC(4)]; 7.00 [s, 1H, HC86)]; 7.20 (s, 1H, NH); 7.50 [m, 1H, HC(5')].

Similarly other lactams of formula II are converted to compounds of Formula I substantially as described above.

CLAIMS

1. process for the production of a compound of Formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug ester thereof,



wherein R is methyl or ethyl;

R₁ is chloro or fluoro;

R₂ is hydrogen or fluoro;


R₃ is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy;

R₄ is hydrogen or fluoro; and

R₅ is chloro, fluoro, trifluoromethyl or methyl,

provided that R₁, R₂, R₄ and R₅ are not all fluoro when R is ethyl and R₃ is H;

comprising cleaving a lactam of formula II




wherein the symbols are as defined above with a base; and in the above process, if desired, temporarily protecting any interfering reactive groups and then isolating the resulting compound of the invention; and, if desired, converting the free carboxylic acid of the compound of formula I into a pharmaceutically acceptable ester derivative thereof; and/or if desired,


converting the free acid of formula I into a salt or a resulting salt into the free acid or into another salt.

2. A process selected from


a) a process for the production of a lactam of formula II




which comprises oxidizing of a lactam of formula III





b) a process for the production of the lactam of formula II as defined in a) above, which comprises cyclisation of a compound of formula VII



c) a process for the preparation of a compound of formula III as defined above comprising coupling as aniline derivative of formula IV




with a cyclohexanone derivative of formula Va or an amino substituted cyclohexene derivative of formula Vb




wherein R is ethyl or methyl and R' is lower alkyl or similar or NR'2 forms a ring as in piperidine or morpholine.

d) a process for the production of a compound of formula VII which comprises N-acylation of a diphenylamine of formula VIII




with a haloacetyl chloride

e) a process for the preparation of a compound of formula VIII which comprises rearrangement and hydrolysis of a compound of formula IX.



;


f) a process for the production of a compound of formula VIII which comprises coupling of a halobenzene derivative of formula XI with p-toluidine or 4-ethyl-aniline



where X is a halogen


g) a process for the production of a compound of formula VIII as defined in d) above which comprises coupling an aniline derivative of formula IV as defined in c) above with 4-bromotoluene or 1-ethyl-4-bromobenzene

h) a process for the production of a compound of formula VIII as defined in d) above which comprises cleavage of a compound of formula X




i) a process for the formation of a compound of formula X as defined in h) above which comprises rearrangement of a compound of formula IX as defined in e) above

j) a process for the production of a compound of formula IX as defined in e) above which comprises alkylation of a compound of formula XII




with 2-chloro-N-(4-methylphenyl)acetamide or 2 chloro-N-(4-ethylphenyl)acetamide

- k) a process for the production of a compound of formula VIII as defined in d) above which comprises alkylation of a compound of formula XII as defined in j) above with 2-chloro-N-(4-methylphenyl)acetamide or 2 chloro-N-(4-ethylphenyl)acetamide followed by rearrangement and cleavage
- l) a process for the production of a compound of formula VIII as defined in d) above comprising oxidation of the corresponding compound of formula XIII (or a tautomer thereof)



- m) a process for the production of a compound of formula XIII as defined in l) above which comprises coupling 1-methoxy-4-methylcyclohexa-1,4-diene or 1-methoxy-4-ethylcyclohexa-1,4-diene with an aniline derivative of formula IV as defined in c) above, and
- n) a process for the production of a compound of formula VIII as defined in d) above comprising coupling 1-methoxy-4-methylcyclohexa-1,4-diene or 1-methoxy-4-ethylcyclohexa-1,4-diene with an aniline derivative of formula IV as defined in c) above, followed by oxidation,
wherein the symbols are as defined in claim 1.

3. A process for the preparation of a compound of formula I as defined in claim 1.



which comprises one or more of processes a) to n) as defined in claim 2 and optionally a process according to claim 1.

4. A process according to claim 3 for the preparation of a compound selected from:

5-methyl-2-(2',4'-dichloro-6'-methylanilino)phenylacetic acid;
 5-methyl-2-(2', 3', 5', 6'-tetrafluoroanilino)phenylacetic acid;
 5-methyl-2-(2', 3', 4', 6'-tetrafluoroanilino)phenylacetic acid;
 5-methyl-2-(2',6'-dichloroanilino)phenylacetic acid;
 5-methyl-2-(2',6'-dichloroanilino)phenylacetic acid, potassium salt;
 5-methyl-2-(2',6'-dichloroanilino)phenylacetic acid, sodium salt;
 5-methyl-2-(2'-chloro-6'fluoroanilino)phenylacetic acid;
 5-methyl-2-(2',6'-dichloro-4'-methylanilino)phenylacetic acid;
 5-methyl-2-(2'-chloro-6'-methylanilino)phenylacetic acid;
 5-methyl-2-(2',4'-difluoro-6'-chloroanilino)phenylacetic acid;
 5-methyl-2-(2'-fluoro-4',6'-dichloroanilino)phenylacetic acid;
 5-methyl-2-(2'-chloro-4'-fluoro-6'-methylanilino)phenylacetic acid;
 5-ethyl-2-(2'-fluoro-6'-chloroanilino)phenylacetic acid;
 5-ethyl-2-(2'-chloro-6'-methylanilino)phenylacetic acid;
 5-ethyl-2-(2',3',6'-trifluoroanilino)phenylacetic acid;


5-ethyl-2-(2',3',5',6'-tetrafluoro-4'-ethoxyanilino)phenylacetic acid;
5-ethyl-2-(2'-chloro-4',6'-difluoroanilino)phenylacetic acid;
5-ethyl-2-(2',4'-dichloro-6'-fluoroanilino)phenylacetic acid;
5-ethyl-2-(2',4'-dichloro-6'-methylanilino)phenylacetic acid;
5-ethyl-2-(2'-fluoro-4'-chloro-6'-methylanilino)phenylacetic acid;
5-ethyl-2-(2',4'-difluoro-6'-methylanilino)phenylacetic acid;
5-ethyl-2-(2'-chloro-4'-fluoro-6'-methylanilino)phenylacetic acid;
5-methyl-2-(2'-chloro-4'-hydroxy-6'-fluoroanilino)phenylacetic acid;
5-methyl-2-(2'-fluoro-6'-trifluoromethylanilino)phenylacetic acid, and
5-methyl-2-(2',4'-dichloro-6'-trifluoromethylanilino)phenylacetic acid,
and pharmaceutically acceptable salts thereof; and pharmaceutically acceptable
prodrug esters thereof.

5. A process according to claim 3 for the preparation of a compound selected from:

5-methyl-2-(2', 3', 4', 6'-tetrafluoroanilino)phenylacetic acid;
5-methyl-2-(2',6'-dichloroanilino)phenylacetic acid;
5-methyl-2-(2'-chloro-6'fluoroanilino)phenylacetic acid;
5-methyl-2-(2',6'-dichloro-4'-methylanilino)phenylacetic acid;
5-methyl-2-(2'-chloro-6'-methylanilino)phenylacetic acid;
5-methyl-2-(2'-chloro-4'-fluoro-6'-methylanilino)phenylacetic acid;
5-ethyl-2-(2'-fluoro-6'-chloroanilino)phenylacetic acid;
5-ethyl-2-(2'-chloro-6'-methylanilino)phenylacetic acid;
5-ethyl-2-(2',3',6'-trifluoroanilino)phenylacetic acid, and
5-ethyl-2-(2',4'-dichloro-6'-methylanilino)phenylacetic acid,

and pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.


6. A compound of formula I, as defined in claim 1




or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug ester thereof, when prepared by a process as defined in claim 3.

7. A compound selected from


a) a compound of formula II




b) a compound of formula III



c) a compound of formula VII




d) a compound of formula VIII




provided that R is not methyl when all of R₁, R₂, R₃, R₄ and R₅ are fluoro;

e) a compound of formula IX




f) a compound of formula X



or

g) a compound of formula XIII



wherein the symbols are as defined in claim 1.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number
WO 01/23346 A2

(51) International Patent Classification⁷: **C07C 229/00**

[CH/FR]; 4, rue de Genève, F-68300 Saint-Louis (FR).
SEDELMEIER, Gottfried [DE/DE]; Erlenweg 11, 79227
Schallstadt (DE). XU, David [US/US]; 12 Kathryn Drive,
Whippany, NJ 07981 (US).

(21) International Application Number: **PCT/EP00/09346**

(74) Agent: BECKER, Konrad; Novartis AG, Corporate
Intellectual Property, Patent & Trademark Department,
CH-4002 Basel (CH).

(22) International Filing Date:
25 September 2000 (25.09.2000)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: **English**

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: **English**

Published:

— *Without international search report and to be republished
upon receipt of that report.*

(30) Priority Data:
9922830.6 27 September 1999 (27.09.1999) **GB**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(71) Applicant (for all designated States except AT, US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, D-4058 Basel (CH).

(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ACEMOGLU, Murat [CH/CH]; Grellingerstrasse 53, CH-4052 Basel (CH). ALLMENDINGER, Thomas [DE/DE]; Lettenweg 1a, 79539 Lörrach (DE). CALIENNI, John, Vincent [US/US]; 2 Edward Place, Cranford, NJ 07016 (US). CERCUS, Jacques [FR/FR]; Rue des Jardiniers 1 E, F-68170 Rixheim (FR). LOISELEUR, Olivier

(54) Title: PROCESS FOR PHENYLACETIC ACID DERIVATIVES



(57) Abstract: A process for the production of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug ester thereof, comprising cleaving a lactam of formula (II) wherein the symbols are as defined, with a base; and precursors therefor and processes for the preparation of the precursors. The compounds of formula (I) are pharmaceutically active compounds which are selective inhibitors of Cyclooxygenase (II).

WO 01/23346 A2

DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION

Original

Supplemental

Substitute

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

PROCESS FOR PHENYLACETIC ACID DERIVATIVES

the specification of which:

is attached hereto.

was filed on _____ as Application No. _____
(day/month/year)

and, if this box (□) contains an x

was amended on _____
(day/month/year)

was filed as Patent Cooperation Treaty international Application No.

PCT/EP 00/09346 on 25.09.2000
(day/month/year)

and, if this box (□) contains an x

entered the national stage in the United States and was accorded Application No.

and, if this box (□) contains an x

was amended, subsequent to entry into the national stage, on _____
(day/month/year)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above and, if this application was filed as a Patent Cooperation Treaty international application, by any amendments made during the international stage (including any made under Patent Cooperation Treaty Rule 91, Article 19 and Article 34).

I acknowledge my duty to disclose all information which is known by me to be material to the patentability of this application as defined in 37 C.F.R. § 1.56.

I hereby claim the benefit under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate listed below and under 35 U.S.C. §365(a) of any Patent Cooperation Treaty international application(s) designating at least one country other than the United States listed below and have also listed below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application the priority of which is claimed for that subject matter:

COUNTRY/REGION (OR P.C.T.)	APPLICATION No.	FILING DATE (day/month/year)	PRIORITY CLAIMED	
Great Britain	9922830.6	27.09.1999	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. § 119 (e) of any United States provisional application(s) listed below:

APPLICATION NO.	FILING DATE (day/month/year)

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) listed below and under 35 U.S.C. §365(c) of any Patent Cooperation Treaty international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of 35 U.S.C. §112, I acknowledge my duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

United States Application No.	United States Filing Date (day/month/year)	Status (Pending, Abandoned or U.S. Patent No.)	International Application No. and Filing Date (day/month/year)

I hereby appoint the registered practitioners associated with Customer No. 001095, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

If these brackets contain an X [X], I hereby authorize the registered practitioners associated with Customer No. 001095 and any others acting on my behalf to take any action relating to this application based on communications from the Patents and Trademarks Division of Novartis Pharma AG, Basle, Switzerland, or an affiliate thereof or a successor thereto, without direct communication from me.

Please address all communications to the address associated with Customer No. 001095, which is currently Thomas Hoxie, Novartis Corporation, Patent and Trademark Department, 564 Morris Avenue, Summit, NJ 07901-1027.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1 - 00 Full name of sole
or first joint inventor

Murat ACEMOGLU

Inventor's signature

Murat Acemo glu

Date

15.02.02

(day/month/year)

Residence 4052 Basel, Switzerland

Citizenship Switzerland

Post Office Address Grellingerstrasse 53
4052 Basel
Switzerland

IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

2 - 00 Full name of second joint inventor, if any

Thomas ALLMENDINGER

Inventor's signature

Thomas Allmendinger

Date

18.02.2002
(day/month/year)

Residence

79539 Lörrach, Germany

Citizenship

Germany

Post Office Address

**Lettenweg 1a
79539 Lörrach
Germany**

Full name of third joint inventor, if any

John Vincent CALIENNI

Inventor's signature

Date

(day/month/year)

Residence

Cranford, New Jersey, 07016, USA

Citizenship

USA

Post Office Address

**2 Edward Place
Cranford, New Jersey, 07016
USA**

4 - 00 Full name of fourth joint inventor, if any

Jacques CERCUS

Inventor's signature

Jacques Cercus

Date

18.02.2002
(day/month/year)

Residence

68170 Rixheim, France

Citizenship

France


Post Office Address

**Rue des Jardiniers 1 E
68170 Rixheim
France**

5 - 00 Full name of fifth joint inventor, if any

Olivier LOISELEUR

Inventor's signature



Date

11 Feb 2002
(day/month/year)

Residence

68300 Saint-Louis, France FRX

Citizenship

Switzerland

Post Office Address

4, rue de Genève
68300 Saint-Louis
France

6 - 00 Full name of sixth joint inventor, if any

Gottfried SEDELMEIER

Inventor's signature



Date

21. Feb. 2002
(day/month/year)

Residence

79227 Schallstadt, Germany DEX

Citizenship

Germany

Post Office Address

Erlenweg 11
79227 Schallstadt
Germany

Full name of seventh joint inventor, if any

David XU

Inventor's signature

Date

(day/month/year)

Residence

Whippany, New Jersey 07981, USA

Citizenship

USA

Post Office Address

12 Kathryn Drive
Whippany, New Jersey 07981
USA

DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION Original Supplemental Substitute

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

PROCESS FOR PHENYLACETIC ACID DERIVATIVES

the specification of which:

is attached hereto.

was filed on _____ as Application No. _____
(day/month/year)

and, if this box (□) contains an *

was amended on _____
(day/month/year)

was filed as Patent Cooperation Treaty international Application No.

PCT/EP 00/09346 on 25.09.2000
(day/month/year)

and, if this box (□) contains an *

entered the national stage in the United States and was accorded Application No.

_____ and, if this box (□) contains an *

was amended, subsequent to entry into the national stage, on _____
(day/month/year)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above and, if this application was filed as a Patent Cooperation Treaty international application, by any amendments made during the international stage (including any made under Patent Cooperation Treaty Rule 91, Article 19 and Article 34).

I acknowledge my duty to disclose all information which is known by me to be material to the patentability of this application as defined in 37 C.F.R. § 1.56.

I hereby claim the benefit under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate listed below and under 35 U.S.C. §365(a) of any Patent Cooperation Treaty international application(s) designating at least one country other than the United States listed below and have also listed below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application the priority of which is claimed for that subject matter:

COUNTRY/REGION (OR P.C.T.)	APPLICATION No.	FILING DATE (day/month/year)	PRIORITY CLAIMED	
Great Britain	9922830.6	27.09.1999	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. § 119 (e) of any United States provisional application(s) listed below:

APPLICATION NO.	FILING DATE (day/month/year)

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) listed below and under 35 U.S.C. §365(c) of any Patent Cooperation Treaty international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of 35 U.S.C. §112, I acknowledge my duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

United States Application No.	United States Filing Date (day/month/year)	Status (Pending, Abandoned or U.S. Patent No.)	International Application No. and Filing Date (day/month/year)

I hereby appoint the registered practitioners associated with Customer No. 001095, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

If these brackets contain an X [X], I hereby authorize the registered practitioners associated with Customer No. 001095 and any others acting on my behalf to take any action relating to this application based on communications from the Patents and Trademarks Division of Novartis Pharma AG, Basle, Switzerland, or an affiliate thereof or a successor thereto, without direct communication from me.

Please address all communications to the address associated with Customer No. 001095, which is currently Thomas Hoxie, Novartis Corporation, Patent and Trademark Department, 564 Morris Avenue, Summit, NJ 07901-1027.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole
or first joint inventor **Murat ACEMOGLU**

Inventor's signature _____ Date _____
(day/month/year)

Residence **4052 Basel, Switzerland**

Citizenship **Switzerland**

Post Office Address
**Grellingerstrasse 53
4052 Basel
Switzerland**

IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

Full name of second joint inventor, if any **Thomas ALLMENDINGER**


Inventor's signature _____ Date _____
(day/month/year)

Residence **79539 Lörrach, Germany**

Citizenship **Germany**

Post Office Address **Lettenweg 1a
79539 Lörrach
Germany**

3 - **∞** Full name of third joint inventor, if any **John Vincent CALIENNI**

Inventor's signature  Date 12/02/02
(day/month/year)

Residence **Cranford, New Jersey, 07016, USA NJ**

Citizenship **USA**

Post Office Address **2 Edward Place
Cranford, New Jersey, 07016
USA**

Full name of fourth joint inventor, if any **Jacques CERCUS**

Inventor's signature _____ Date _____
(day/month/year)

Residence **68170 Rixheim, France**

Citizenship **France**

Post Office Address **Rue des Jardiniers 1 E
68170 Rixheim
France**

Full name of fifth joint inventor, if any **Olivier LOISELEUR**

Inventor's signature _____ Date _____
(day/month/year)

Residence 68300 Saint-Louis, France

Citizenship Switzerland

Post Office Address **4, rue de Genève
68300 Saint-Louis
France**

Full name of sixth joint inventor, if any **Gottfried SEDELMEIER**


Inventor's signature _____ Date _____
(day/month/year)

Residence 79227 Schallstadt, Germany

Citizenship

Post Office Address **Erlenweg 11
79227 Schallstadt
Germany**

Full name of seventh joint inventor, if any **David XU**

Inventor's signature 

Date 14/02/02
(day/month/year)

Residence Whippny, New Jersey 07981, USA NJ

Citizenship USA

**Post Office Address 12 Kathryn Drive
Whippany, New Jersey 07981
USA**